Where angels feared to tread
Download
1 / 19

Where Angels Feared to Tread - PowerPoint PPT Presentation


  • 210 Views
  • Updated On :

????????????. Where Angels Feared to Tread. Roger Ashby Hunter-Fleming Ltd. Technology Transfer. Experience from both sides Hunter-Fleming, an example Working with universities. HUNTER FLEMING. PHARMACEUTICAL PIPELINE PROVIDERS.  Hunter-Fleming Ltd. Mission.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Where Angels Feared to Tread' - jaden


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Where angels feared to tread l.jpg

????????????

Where Angels Feared to Tread

Roger Ashby

Hunter-Fleming Ltd


Technology transfer l.jpg
Technology Transfer

  • Experience from both sides

  • Hunter-Fleming, an example

  • Working with universities


Hunter fleming l.jpg
HUNTER FLEMING

PHARMACEUTICAL PIPELINE PROVIDERS

 Hunter-Fleming Ltd


Mission l.jpg
Mission

To be a leading, highly profitable, international company supplying novel breakthrough prescription medicines to global marketing companies, in areas of significant unmet medical needs.

PATENT TO PATIENT

 Hunter-Fleming Ltd


Slide5 l.jpg

The Market

 Hunter-Fleming Ltd


Management l.jpg
Management

  • Giles Vardy, Non Exec Chairman, Chairman of AIM Steering Group, former CEO of Greig Middleton, Chairman CQS Management, alternative asset management business

  • Dr Jim Murray, CEO: co-founder of Shire, 29 years in Pharma industry

  • Professor Ernst Wulfert, CSO: former Research Director UCB responsible for the development of three blockbuster drugs – Keppra, Zyrtec, enofibrate

  • Dr. John Fox, Managing Director: Head of Planning at Shire, 20 years in pharmacology & clinical research

  • Neil Hockaday, FD: COO HSBC Corporate Banking

 Hunter-Fleming Ltd


University collaborations l.jpg
University Collaborations

  • Bristol

  • Belfast

  • Southampton

  • St Marianna Hospital, Medical School, Kawasaki

  • Loyola, Chicago

  • CNAM, Paris

  • Kyoto Pharmaceutical University, Japan

  • Tromso, Norway

  • Strathclyde/Glasgow

 Hunter-Fleming Ltd


Slide8 l.jpg

Business Model

VALUE

C

NDA, drug filing

B

“Innovations

Break Point”

A

Basic

Discovery

COST

Basic Research

ACADEMIA

Innovation

HF

Drug Development

BIG PHARMA

 Hunter-Fleming Ltd


Slide9 l.jpg

IntegratedTherapies

anti-neurodegenerative drugs

(brain inflammatory diseases)HF 0220

Neurosciences

(neurodegenerative diseases, AD, PD, stroke, MS…)

Immunology & Inflammation

(RA, Type I diabetes,

asthma, rhinitis, cancer..)

Cardiovascular &

Metabolic Disorders

(CHD, MI, Diabetes…)

Novel cytoprotective drugs

brain, heart, kidney

HF 0220 “follow-ups”

Anti-diabetic

HF 1020

 Hunter-Fleming Ltd


Portfolio l.jpg
Portfolio

 Hunter-Fleming Ltd


Slide11 l.jpg
WHY ?

  • Access to blue sky research

  • Access to intellectual property

  • Access to ongoing research output


Slide12 l.jpg
FACT

  • British Telecom research spend £30m pa

  • Bristol University, -

  • UCL, Imperial College, - £500m pa

  • Southampton University -


Academia l.jpg

ACADEMIA

Solutions seeking applications


Industry l.jpg

INDUSTRY

Paucity of innovative knowledge

cf Pharma 50% all new medicines

in-licensed


Key issues l.jpg
KEY ISSUES

  • Point of contact

  • Executive authority

  • Ability to deliver – Willing scientists

  • - Secured IP

  • Continuity


Deal breakers l.jpg
Deal Breakers

  • Valuation of IP and / or Know how

  • Limitation of management expertise


Decision l.jpg
Decision

  • Licence OR

  • Start up new company


Hunter fleming18 l.jpg
Hunter-Fleming

  • Mature management team

  • Proven track record

  • Understand university’s modus operandi

  • Enduring partnership

  • Virtual circle taking IP to market

  • Financial returns to all- University

  • - Research Staff

  • - H-F shareholders